Loading
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
Latest quote
$1.10
+$0.02 · +1.85%
After-hours
$1.10
$0.00 · 0.00%
Sep 10, 4:10 PM ET
Regular session · ET · Market data may be delayed.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
Day range
Current $1.10
52-week range
Current $1.10
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
48
Fair Value
Sentiment
41
Mixed
Risk
69
High Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
Day range
Current $1.10
52-week range
Current $1.10
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 2.5M USD | — | 2.5M USD | — | — |
| Gross profit | −2.5M USD | — | −2.5M USD | — | — |
| Research and development | 10.21M USD | 16.96M USD | 16.83M USD | 14.06M USD | 7.35M USD |
| Selling, general, and administrative | 9.65M USD | 12.64M USD | 13.51M USD | 14.46M USD | 7.31M USD |
| Operating expenses | 17.36M USD | 30.44M USD | 27.84M USD | 28.52M USD | 14.65M USD |
| Interest income | 421K USD | 230K USD | — | — | — |
| Depreciation and amortization | 2.5M USD | 2.66M USD | 2.5M USD | 1.1M USD | 788K USD |
| Operating income | −19.86M USD | −30.44M USD | −30.34M USD | −28.52M USD | −14.65M USD |
| Net income | −19.44M USD | −30.44M USD | −30.01M USD | −28.52M USD | −14.65M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$4.00
263.64% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 6, 2025 | 1:30 | — | — |
Effective Jun 6, 2025
1:30
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
